drugset / Trial / NCT02449603

Summary

This is a multi-centre, open-label, randomized, parallel trial to compare the effect of Exenatide versus Biphasic insulin Aspart 30 on glucose variability and inflammatory markers in type 2 diabetes mellitus (T2DM) patients inadequately controlled with metformin monotherapy.

Timeline

Start
2015-11
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug
Comparator biphasic insulin aspart 30 Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Comparator biphasic insulin aspart 30 Protein / enzyme biologic 0.4 iu/kg Subcutaneous
Comparator biphasic insulin aspart 30 Protein / enzyme biologic 10 iu Subcutaneous
Comparator biphasic insulin aspart 30 Protein / enzyme biologic 12 iu Subcutaneous